AstraZeneca announced today that its Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in the European Union for first-line treatment of adult patients with advanced Epidermal Growth Factor Receptor Mutation (EGFRm) non-small cell lung cancer (NSCLC) with exon 19 deletion or exon 21 (L858R) mutation. (WuXi AppTec WeChat official account)
一线治疗晚期癌症！阿斯利康小分子组合疗法再获批准
First-line treatment for advanced cancer! Astrazeneca's small molecule combination therapy approved again.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.